-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Some patients with coronavirus disease (COVID-19) in 2019 have serious complications due to excessive immune response.
fluvoxamine is a selective 5-serotonin reuptake inhibitor (SSRI), mainly used in patients with obsessive compulsive disorder.
in sepsis mouse models, fluvosamine can reduce inflammatory damage.
researchers recently examined its role in preventing clinical deterioration and reducing the severity of the disease in patients with neo-coronary pneumonia.
This study was conducted in a placebo-controlled, double-blind, randomized, completely remote (non-contact) clinical trial involving patients with severe acute respiratory syndrome coronavirus type 2 infection in adults who were not hospitalized, who developed COVID-19 symptoms within 7 days, had oxygen saturation of 92% or higher, and randomly received 100 mg of fluorofoxamine (n=80) or placebo (n=72), three times a day for 15 consecutive days. The main results of the
study were clinical deterioration within 15 days of randomization, meeting two criteria: (1) shortness of breath or hospitalization for shortness of breath or pneumonia;
152 patients, with an average age of 46, 72 per cent female and 115 (76 per cent) completed the trial.
clinical deterioration was reported in 80 patients in the fluorofosamine group, and 6 out of 72 patients in the placebo group showed clinical deterioration (with an absolute difference of 8.7%).
1 case of serious adverse events and 11 other adverse events in the fluorofsamine group, while 6 cases of severe adverse events and 12 other adverse events were reported in the placebo group.
study concluded that for patients with mild neo-coronary pneumonia receiving outpatient treatment, receiving fluorofosamine treatment could help reduce the risk of clinical deterioration within 15 days, but larger studies are needed to determine the clinical efficacy of fluorovolsamine in preventing the deterioration of neo-crown pneumonia patients.
